Retrophin Stock Price, News & Analysis (NASDAQ:RTRX)

$21.51 -0.04 (-0.19 %)
(As of 12/11/2017 01:37 PM ET)
Previous Close$21.55
Today's Range$21.32 - $21.99
52-Week Range$15.55 - $26.44
Volume196,600 shs
Average Volume325,108 shs
Market Capitalization$845.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.96

About Retrophin (NASDAQ:RTRX)

Retrophin logoRetrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Debt-to-Equity Ratio0.15%
Current Ratio3.88%
Quick Ratio3.83%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$133.59 million
Price / Sales6.33
Cash Flow$0.59 per share
Price / Cash36.46
Book Value$8.16 per share
Price / Book2.64

Profitability

Trailing EPS($1.51)
Net Income$-47,900,000.00
Net Margins-33.79%
Return on Equity-10.13%
Return on Assets-5.94%

Miscellaneous

Employees135
Outstanding Shares39,310,000

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin, Inc. (NASDAQ:RTRX) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.21. The biopharmaceutical company had revenue of $40.34 million for the quarter, compared to analysts' expectations of $40.51 million. Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company's quarterly revenue was up 18.8% compared to the same quarter last year. During the same period last year, the business earned ($0.09) earnings per share. View Retrophin's Earnings History.

Where is Retrophin's stock going? Where will Retrophin's stock price be in 2017?

3 equities research analysts have issued 1-year target prices for Retrophin's stock. Their forecasts range from $28.00 to $44.00. On average, they anticipate Retrophin's stock price to reach $36.00 in the next year. View Analyst Ratings for Retrophin.

What are Wall Street analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:

  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (11/14/2017)
  • 2. BMO Capital Markets analysts commented, "We maintain our Outperform rating on RTRX shares following Retrophin's announcement to initiate a Phase III trial in 2H17 for Sparsentan. Our price target decreases to $45 from $46, as we push back Sparsentan estimates by two years, but increase our probability of success to 75% from 55%. We believe FDA agreement for proteinuria as an approvable endpoint removes significant uncertainty around Sparsentan's regulatory path as well as avoids a lengthy trial requiring eGFR or kidney survival as endpoints. We estimate Sparsentan peak sales (US only) of $1bn." (3/2/2017)

Who are some of Retrophin's key competitors?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:

  • Gary A. Lyons, Independent Chairman of the Board (Age 66)
  • Stephen J. Aselage, President, Chief Executive Officer, Director (Age 65)
  • Laura M. Clague CPA, Chief Financial Officer, Senior Vice President (Age 58)
  • Neil McFarlane, Chief Operating Officer (Age 44)
  • Elizabeth E. Reed, Senior Vice President, General Counsel and Corporate Secretary (Age 46)
  • William E. Rote Ph.D., Senior Vice President and Head of Research and Development (Age 54)
  • Roy D. Baynes M.D. Ph.D., Independent Director (Age 62)
  • Timothy P. Coughlin CPA, Independent Director (Age 50)
  • John W. Kozarich, Independent Director (Age 67)
  • Jeffrey A. Meckler, Independent Director (Age 50)

Who owns Retrophin stock?

Retrophin's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.83%), Macquarie Group Ltd. (3.80%), Jennison Associates LLC (3.64%), Dimensional Fund Advisors LP (2.28%), Oak Ridge Investments LLC (1.93%) and Point72 Asset Management L.P. (1.21%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Neil F Mcfarlane and Steve Aselage. View Institutional Ownership Trends for Retrophin.

Who sold Retrophin stock? Who is selling Retrophin stock?

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Jennison Associates LLC, Oak Ridge Investments LLC, Sphera Funds Management LTD., Boston Advisors LLC, California State Teachers Retirement System, JPMorgan Chase & Co. and GSA Capital Partners LLP. View Insider Buying and Selling for Retrophin.

Who bought Retrophin stock? Who is buying Retrophin stock?

Retrophin's stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Prudential Financial Inc., American Century Companies Inc., Fisher Asset Management LLC, Dimensional Fund Advisors LP, Strs Ohio, OxFORD Asset Management LLP and Wells Fargo & Company MN. View Insider Buying and Selling for Retrophin.

How do I buy Retrophin stock?

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of Retrophin stock can currently be purchased for approximately $21.51.

How big of a company is Retrophin?

Retrophin has a market capitalization of $845.49 million and generates $133.59 million in revenue each year. The biopharmaceutical company earns $-47,900,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Retrophin employs 135 workers across the globe.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (RTRX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Retrophin (NASDAQ:RTRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $34.67$34.67$35.00$35.00
Price Target Upside: 40.12% upside40.12% upside97.18% upside97.18% upside

Retrophin (NASDAQ:RTRX) Consensus Price Target History

Price Target History for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ:RTRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017BMO Capital MarketsReiterated RatingBuy$44.00N/AView Rating Details
4/6/2017William BlairReiterated RatingOutperformMediumView Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00N/AView Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Retrophin (NASDAQ:RTRX) Earnings History and Estimates Chart

Earnings by Quarter for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ RTRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.25)($0.46)$40.51 million$40.34 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.24)($0.34)$37.36 million$38.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.22)$0.01$36.20 million$33.62 millionViewListenView Earnings Details
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.23 million$17.37 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)$8.35 millionViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Retrophin (NASDAQ:RTRX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.19)($0.22)
Q2 20172($0.25)($0.19)($0.22)
Q3 20172($0.28)($0.18)($0.23)
Q4 20172($0.29)($0.17)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Retrophin (NASDAQ:RTRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Retrophin (NASDAQ RTRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.87%
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)
Insider Trades by Quarter for Retrophin (NASDAQ:RTRX)

Retrophin (NASDAQ RTRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Neil F McfarlaneCOOSell1,378$22.50$31,005.00View SEC Filing  
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Retrophin (NASDAQ RTRX) News Headlines

Source:
DateHeadline
Retrophin (RTRX) and Its Competitors Financial ReviewRetrophin (RTRX) and Its Competitors Financial Review
www.americanbankingnews.com - December 6 at 5:30 PM
A Martin Shkreli Trial Without the Outbursts, Anger or `TrashyA Martin Shkreli Trial Without the Outbursts, Anger or `Trashy'
finance.yahoo.com - December 6 at 3:23 PM
 Brokerages Expect Retrophin, Inc. (RTRX) Will Announce Quarterly Sales of $40.50 Million Brokerages Expect Retrophin, Inc. (RTRX) Will Announce Quarterly Sales of $40.50 Million
www.americanbankingnews.com - December 6 at 9:50 AM
$0.17 EPS Expected for Retrophin, Inc. (RTRX) This Quarter$0.17 EPS Expected for Retrophin, Inc. (RTRX) This Quarter
www.americanbankingnews.com - December 4 at 1:30 PM
Head to Head Contrast: Retrophin (RTRX) & The CompetitionHead to Head Contrast: Retrophin (RTRX) & The Competition
www.americanbankingnews.com - December 2 at 3:06 PM
Retrophin to Present at the BMO 2017 Prescriptions for Success Healthcare ConferenceRetrophin to Present at the BMO 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 1 at 8:15 AM
Retrophin, Inc. (RTRX) Given Consensus Recommendation of "Buy" by AnalystsRetrophin, Inc. (RTRX) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 21 at 3:52 AM
Retrophin, Inc. (RTRX) Cut to Sell at ValuEngineRetrophin, Inc. (RTRX) Cut to Sell at ValuEngine
www.americanbankingnews.com - November 20 at 10:20 PM
Analyzing Retrophin (RTRX) and Its RivalsAnalyzing Retrophin (RTRX) and Its Rivals
www.americanbankingnews.com - November 20 at 3:09 AM
Retrophin, Inc. (RTRX) Expected to Post Earnings of $0.17 Per ShareRetrophin, Inc. (RTRX) Expected to Post Earnings of $0.17 Per Share
www.americanbankingnews.com - November 16 at 1:04 AM
Zacks Investment Research Lowers Retrophin, Inc. (RTRX) to Strong SellZacks Investment Research Lowers Retrophin, Inc. (RTRX) to Strong Sell
www.americanbankingnews.com - November 14 at 7:50 AM
William Blair Equities Analysts Reduce Earnings Estimates for Retrophin, Inc. (RTRX)William Blair Equities Analysts Reduce Earnings Estimates for Retrophin, Inc. (RTRX)
www.americanbankingnews.com - November 13 at 2:14 AM
Analyzing Retrophin (RTRX) & Microbot Medical (MBOT)Analyzing Retrophin (RTRX) & Microbot Medical (MBOT)
www.americanbankingnews.com - November 12 at 5:26 AM
Retrophin, Inc. to Host Earnings CallRetrophin, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:47 PM
Retrophin Reports Third Quarter 2017 Financial ResultsRetrophin Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 12:47 PM
Retrophin reports 3Q lossRetrophin reports 3Q loss
finance.yahoo.com - November 9 at 12:47 PM
Edited Transcript of RTRX earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of RTRX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 12:47 PM
Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : November 8, 2017Retrophin, Inc. breached its 50 day moving average in a Bullish Manner : RTRX-US : November 8, 2017
finance.yahoo.com - November 9 at 12:47 PM
Retrophin, Inc. (RTRX) Issues Quarterly  Earnings ResultsRetrophin, Inc. (RTRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 5:37 PM
Retrophin to Present at the Jefferies 2017 London Healthcare ConferenceRetrophin to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 4 at 12:40 PM
Retrophin Reports Additional Positive Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)Retrophin Reports Additional Positive Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
finance.yahoo.com - November 4 at 12:40 PM
$40.82 Million in Sales Expected for Retrophin, Inc. (RTRX) This Quarter$40.82 Million in Sales Expected for Retrophin, Inc. (RTRX) This Quarter
www.americanbankingnews.com - October 28 at 4:56 AM
Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : October 26, 2017Retrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : October 26, 2017
finance.yahoo.com - October 27 at 3:32 PM
Retrophin, Inc. (RTRX) Given Average Rating of "Buy" by AnalystsRetrophin, Inc. (RTRX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 27 at 3:28 AM
Retrophin to Report Third Quarter 2017 Financial ResultsRetrophin to Report Third Quarter 2017 Financial Results
finance.yahoo.com - October 25 at 10:06 AM
Shkreli Lawyer, on Trial Himself, Seeks Distance From ShkreliShkreli Lawyer, on Trial Himself, Seeks Distance From Shkreli
finance.yahoo.com - October 20 at 4:39 PM
Lawyer charged alongside Martin Shkreli goes on trialLawyer charged alongside Martin Shkreli goes on trial
finance.yahoo.com - October 20 at 4:39 PM
Edited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMTEdited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMT
finance.yahoo.com - October 17 at 3:27 PM
Adviser or Accomplice? Spotlight Moves to Shkreli’s Ex-LawyerAdviser or Accomplice? Spotlight Moves to Shkreli’s Ex-Lawyer
finance.yahoo.com - October 17 at 6:54 AM
[$$] Jury Selection to Begin in Trial of Martin Shkreli’s Lawyer[$$] Jury Selection to Begin in Trial of Martin Shkreli’s Lawyer
finance.yahoo.com - October 16 at 6:16 AM
Retrophin, Inc. (RTRX) Rating Reiterated by BMO Capital MarketsRetrophin, Inc. (RTRX) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - October 7 at 4:20 PM
Retrophin (RTRX) Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at CNSRetrophin (RTRX) Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at CNS
www.streetinsider.com - October 6 at 7:55 AM
Retrophin Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at the Child Neurology Society’s 26th Annual MeetingRetrophin Announces Presentation of New Data from Physician-Initiated Treatment with Fosmetpantotenate at the Child Neurology Society’s 26th Annual Meeting
finance.yahoo.com - October 6 at 7:55 AM
Retrophin, Inc. :RTRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017Retrophin, Inc. :RTRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 3 at 11:57 AM
ETFs with exposure to Retrophin, Inc. : October 2, 2017ETFs with exposure to Retrophin, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 11:57 AM
Retrophin, Inc. (RTRX) Receives Average Recommendation of "Buy" from AnalystsRetrophin, Inc. (RTRX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 2 at 12:44 AM
Biopharmx Corp (BPMX) vs. Retrophin (RTRX) Financial ReviewBiopharmx Corp (BPMX) vs. Retrophin (RTRX) Financial Review
www.americanbankingnews.com - September 24 at 4:32 AM
Retrophin, Inc. (RTRX) Expected to Post Quarterly Sales of $40.82 MillionRetrophin, Inc. (RTRX) Expected to Post Quarterly Sales of $40.82 Million
www.americanbankingnews.com - September 20 at 3:56 AM
Martin Shkreli's new jailhouse home is 'not where you want to be': Defense lawyerMartin Shkreli's new jailhouse home is 'not where you want to be': Defense lawyer
finance.yahoo.com - September 16 at 8:15 AM
Shkreli could get locked up Wednesday if bail revoked over bizarre Hillary Clinton hair stuntShkreli could get locked up Wednesday if bail revoked over bizarre Hillary Clinton hair stunt
finance.yahoo.com - September 13 at 9:42 PM
Retrophin to Present at September Investor ConferencesRetrophin to Present at September Investor Conferences
feeds.benzinga.com - September 11 at 6:30 PM
Martin Shkreli seeks to overturn part of his convictionMartin Shkreli seeks to overturn part of his conviction
finance.yahoo.com - September 9 at 8:07 AM
Noteworthy Thursday Option Activity: HDS, RTRX, KRNoteworthy Thursday Option Activity: HDS, RTRX, KR
www.nasdaq.com - September 8 at 7:52 AM
Retrophin, Inc. (RTRX) Given Consensus Rating of "Buy" by AnalystsRetrophin, Inc. (RTRX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 7 at 12:30 AM
Allergan: Restasis Patent Battle Could Test Senates Resolve - Seeking AlphaAllergan: Restasis Patent Battle Could Test Senate's Resolve - Seeking Alpha
seekingalpha.com - September 6 at 7:52 AM
Retrophin (RTRX) Reports Cooperative Research and Development Agreement with NCATS and NGLY1.org - StreetInsider.comRetrophin (RTRX) Reports Cooperative Research and Development Agreement with NCATS and NGLY1.org - StreetInsider.com
www.streetinsider.com - September 6 at 7:52 AM
Retrophin Announces Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 DeficiencyRetrophin Announces Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency
finance.yahoo.com - September 6 at 7:52 AM
Head to Head Contrast: Progenics Pharmaceuticals (PGNX) versus Retrophin (RTRX)Head to Head Contrast: Progenics Pharmaceuticals (PGNX) versus Retrophin (RTRX)
www.americanbankingnews.com - August 25 at 4:10 AM
Pharma bro Martin Shkreli: I dont think Im going to jailPharma bro Martin Shkreli: 'I don't think I'm going to jail'
finance.yahoo.com - August 23 at 11:02 AM
Retrophin, Inc. (RTRX) COO Sells $31,005.00 in StockRetrophin, Inc. (RTRX) COO Sells $31,005.00 in Stock
www.americanbankingnews.com - August 17 at 10:48 PM

SEC Filings

Retrophin (NASDAQ:RTRX) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Retrophin (NASDAQ:RTRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Retrophin (NASDAQ RTRX) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.